Tango Therapeutics Management
Management criteria checks 3/4
Tango Therapeutics' CEO is Malte Peters, appointed in Jan 2026, has a tenure of 7.33 years. directly owns 0.008% of the company’s shares, worth $138.88K. The average tenure of the management team and the board of directors is 2.1 years and 4.9 years respectively.
Key information
Malte Peters
Chief executive officer
US$292.4k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.008% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues
Jan 19
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%
Dec 05Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy
Nov 21Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected
Sep 17US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results
May 15Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding
Apr 14Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation
Apr 04Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Feb 28Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%
Feb 28Tango Therapeutics: Chance For A Short Squeeze
Jan 23Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?
Dec 05Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 31Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Sep 10What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You
Sep 01Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%
Jun 29Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why
May 30Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06CEO
Malte Peters (63 yo)
Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chair | 8.8yrs | US$6.54m | 1.08% $ 18.0m | |
| President | no data | US$292.40k | 0.0083% $ 138.9k | |
| Chief Financial Officer | 9.3yrs | US$3.17m | 0.073% $ 1.2m | |
| Chief Compliance Officer & Corporate Secretary | 4.4yrs | US$2.09m | 0.017% $ 290.9k | |
| President of Research & Development | 2.9yrs | US$3.78m | 0.052% $ 860.7k | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Technical Operations Officer | 2yrs | no data | no data | |
| Chief Scientific Officer | 2.3yrs | no data | no data | |
| VP of IR & Corporate Communications | less than a year | no data | no data | |
| Chief Human Resources Officer | 1.8yrs | no data | no data |
Experienced Management: TNGX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chair | 8.8yrs | US$6.54m | 1.08% $ 18.0m | |
| President | 7.3yrs | US$292.40k | 0.0083% $ 138.9k | |
| Founder & Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Lead Independent Director | 8.8yrs | US$318.40k | 0.0083% $ 138.9k | |
| Independent Director | 4.8yrs | US$296.15k | 0.023% $ 385.9k | |
| Independent Director | 2.2yrs | no data | no data | |
| Independent Director | 4.8yrs | US$300.65k | 0.0046% $ 77.2k | |
| Independent Director | 2.4yrs | US$226.43k | 0.0060% $ 99.0k | |
| Director | no data | no data | no data | |
| Member of Scientific Advisory Board | 1yr | US$1.88m | no data |
Experienced Board: TNGX's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 05:21 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tango Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Chris Shibutani | Goldman Sachs |